Therapeutic effect of autologous platelet-rich plasma (PRP) on recalcitrant cutaneous ulcers in livedoid vasculopathy

Tamihiro Kawakami, MD, PhD, Sora Takeuchi, MD, PhD, Tatsuro Okano, MD, Hajime Inoue, MD, PhD, and Yoshinao Soma, MD, PhD
Kawasaki, Japan

Key words: antiplatelet; livedoid vasculopathy; platelet-rich plasma; recalcitrant cutaneous ulcer.

Livedoid vasculopathy is a chronic disorder diagnosed based on clinical features such as cutaneous ulcers, atrophic, stellate scars with peripheral telangiectasis and hyperpigmentation. Platelet-rich plasma (PRP) therapy has been successfully used in the treatment of various dermatologic conditions including pressure ulcers, diabetic ulcers, and posttraumatic ulcers. The most common PRP therapy is to obtain a sample of blood directly from the patient (autologous).

CASE REPORT

A 50-year-old Japanese woman presented with a 20-year history of painful, hyperpigmented, hard, contracted skin with recalcitrant cutaneous ulcers on her lower extremities. She was previously treated with systemic conventional therapies such as prednisolone and warfarin. However, the skin lesions progressed to painful ulcers with eschars and granulation tissue during the last 6 months (Fig 1). Her lower extremities exhibited vascular engorgement in a livedoid pattern over her legs. A biopsy showed dermal fibrosis, intravascular hyalinized material of fibrin-containing thrombi with cell inflammation, and capillary dilatation in the papillary to middle dermis consistent with the clinical diagnosis of livedoid vasculopathy (Fig 2).

Bacterial culture and Gram stain were negative. We obtained 60 mL of peripheral autologous blood, collected into tubes containing acid-citrate-dextrose solution formula anticoagulant. The citrated blood was centrifuged for 15 minutes at 2700 rpm. The supernatant (called “platelet-poor plasma”) was removed from the platelet sedimentation after centrifugation, and then the PRP was adjusted at 10-fold concentrations by using 6 mL of platelet-poor plasma. After completion of 3 cycles of autologous PRP treatments at monthly intervals, the lesion showed improvement with atrophic scars and minimal pain (Fig 3). During the PRP therapy, the patient received nonsteroidal anti-inflammatory drug.

DISCUSSION

Pathogenesis of livedoid vasculopathy remains unclear and classification is difficult as a result of variable nomenclature and the multifactorial nature of the disease. Idiopathic forms, association with immune complex, and dermal blood vessel occlusion have been described. There is, however,
increasing evidence that the condition must be mediated by either coagulation or fibrinolysis disorders.\textsuperscript{5,7} Systemic therapeutic recommendations mainly refer to antiplatelet, antithrombotic, anticoagulant, and fibrinolytic medications, which are often unsatisfactory.\textsuperscript{1,8,9} We believe this is the first report of successful treatment of recalcitrant cutaneous ulcers in a patient with livedoid vasculopathy by autologous PRP. We propose that autologous PRP therapy could be an appropriate alternative modality when the degree of healing with conventional treatment appears to be unsatisfactory.

PRP consists of a high concentration of platelets that promote wound healing through chemotaxis, cell proliferation, angiogenesis, and tissue remodeling. Platelets are critically important in the wound-healing process. They translocate rapidly to the wound site and adhere to the damaged tissue, initiating a healing reaction that includes the release of various cytokines and growth factors. Topical application of PRP to acute and chronic skin ulcers significantly accelerated the epithelization process, likely through up-regulation of the cell cycle regulatory proteins cyclin A and CDK4.\textsuperscript{10} We propose that these mechanisms could accelerate the healing of recalcitrant cutaneous ulcers in livedoid vasculopathy. Additional randomized, controlled clinical trials are required to adequately address the localized treatment effects.

REFERENCES

1. Alavi A, Hafner J, Dutz JP, et al. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. \textit{J Am Acad Dermatol}. 2013;69:1033-1042.
2. Sell SA, Ericksen JJ, Reis TW, Droste LR, Bhuiyan MB, Gater DR. A case report on the use of sustained release platelet-rich plasma for the treatment of chronic pressure ulcers. \textit{J Spinal Cord Med}. 2011;34:122-127.
3. Villela DL, Santos VL. Evidence on the use of platelet-rich plasma for diabetic ulcer: a systemic review. \textit{Growth Factors}. 2010;28:111-116.
4. McCalmont CS, McCalmont TH, Jorizzo JL, et al. Livedo vasculitis: vasculitis or thrombotic vasculopathy? \textit{Clin Exp Dermatol}. 1992;17:4-8.
5. Hegemann B, Helmbold P, Marsch WC. Livedoid vasculitis with ulcerations: the role of antithrombin III deficiency and its therapeutic consequences. \textit{Arch Dermatol}. 2002;138:841-842.
6. Hairston BR, Davis MD, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. \textit{Arch Dermatol}. 2006;142:1413-1418.
7. Di Giacomo TB, Hussein TP, Souza DG, Criado PR. Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs—a prospective study. \textit{J Eur Acad Dermatol Venereol}. 2010;24:1340-1346.
8. Callen JP. Livedoid vasculopathy: what is it and how the patient should be evaluated and treated. \textit{Arch Dermatol}. 2006;142:1481-1482.
9. Gonzalez-Santiago TM, Davis MD. Update of management of connective tissue diseases: livedoid vasculopathy. \textit{Dermatol Ther}. 2012;25:183-194.
10. Kim SA, Ryu HW, Lee KS, Cho JW. Application of platelet-rich plasma accelerates the wound healing process in acute and chronic ulcers through rapid migration and upregulation of cyclin A and CDK4 in HaCaT cells. \textit{Mol Med Rep}. 2013;7:476-480.